Uncontrolled bleeding remains a major problem in intensive care and emergency medicine which still requires effective and innovative treatment options. This editorial highlights that there is growing evidence on the efficacy of rFVIIa (Novoseven) in controlling such bleeding, and that clinical trials in different patient populations are required to assess its efficacy and safety.

– M. Aldouri